Shield and Axis agree terms of merger:
This article was originally published in Clinica
Executive Summary
Shield Diagnostics and Axis Biochemicals have agreed the terms of their all-share merger - which will result in Shield shareholders owning 54.4% of the new company and Axis the remaining 45.6%. Under the original proposal which was announced in December, Shield would have held 62% of the company. Shield plans to raise £12 million ($19 million) in a rights issue to fund the costs of the merger and for working capital.
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.